Due to the overexpression of CXCR4 in ovarian cancer, AMD-NP-PTX can be effectively delivered to the cancer site, inhibiting the CXCL12-CXCR4 axis and exerting chemotherapeutic activity with reduced off-target toxicity. The gene discussed is CXCL12; the disease is cancer.